Cases & Deals

  • Home
  • Practices
  • Merck unit resolves DJ action involving pneumococcal vaccine patents

Share

Merck unit resolves DJ action involving pneumococcal vaccine patents

September 2021

Client(s) Merck & Co., Inc.

Jones Day represented Merck Sharp & Dohme Corp. in an action in Delaware district court against Pfizer (through its subsidiaries including Wyeth, LLC) involving several patents on Wyeth’s vaccine technology. The case related to Merck’s new 15-valent pneumococcal conjugate vaccine, known as Vaxneuvance. The matter was dismissed as a result of a worldwide settlement.

Merck Sharp & Dohme Corp. v. Wyeth LLC, No. 1-21-cv-00024 (D. Del.)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.